News - Alkermes, Research

Filter

Current filters:

AlkermesResearch

Popular Filters

Alkermes reveals candidates for MS, cancer and pain

18-07-2013

US drugmaker Alkermes (Nasdaq: ALKS) has unveiled three new drug candidates for the treatment of multiple…

AlkermesBiogen IdecNeurologicalNorth AmericaOncologyPharmaceuticalResearchTecfidera

Alkermes boosted by positive Ph II data on ALKS 5461 for major depressive disorder

18-04-2013

Ireland-headquartered Alkermes (Nasdaq: ALKS) saw its shares rise 16% to $29.72, after it announced positive…

AlkermesNeurologicalPharmaceuticalResearch

Alkermes and J&J initiate Ph III trial of three-month Invega Sustenna

12-06-2012

USA-based Alkermes (Nasdaq: ALKS) and partner health care giant Johnson & Johnson (NYSE: JNJ) have started…

AlkermesInvega SustennaJohnson & JohnsonNeurologicalPharmaceuticalResearch

Strong results for Alkermes’ ALKS 5461 in major depressive disorder

04-01-2012

US drugmaker Alkermes (Nasdaq: ALKS) yesterday released positive early clinical results for a central…

AlkermesAripiprazoleNeurologicalPharmaceuticalResearch

Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS

13-09-2011

A significantly higher proportion of patients reached the target for blood sugar control (HbA1c target…

AlkermesAmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top